Botulinum toxin therapy improves masseter spasticity in Amyotrophic Lateral Sclerosis

Area of Science:

• Neurology
• Gastroenterology

Background:

• Amyotrophic lateral sclerosis (ALS) can cause masseter spasticity, leading to significant patient discomfort and functional impairment.
• Symptoms such as trismus, lip/cheek biting, and jaw clonus are common challenges for ALS patients.

Purpose of the Study:

• To evaluate the efficacy of botulinum toxin type A (BoNT-A) injections in managing masseter spasticity in patients with ALS.
• To assess the impact of BoNT-A treatment on daily living activities and patient comfort.

Main Methods:

• A retrospective analysis of medical records was conducted for 12 ALS patients who received BoNT-A injections in the masseter muscles.
• The effects of the first injection were assessed one month post-administration.

Main Results:

• Eight out of twelve patients reported significant symptom relief, including reduced trismus, tongue, lip, and cheek biting, and jaw clonus.
• Five patients experienced improved ease of dental care following the injections.
• BoNT-A injections demonstrated a clear reduction in masseter spasticity.

Conclusions:

• Botulinum toxin type A injections are an effective therapeutic option for reducing masseter spasticity in ALS patients.
• Treatment with BoNT-A significantly enhances the quality of life and daily comfort for individuals with ALS experiencing these specific symptoms.